Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clinuvel Pharmaceuticals Limited has lodged an Appendix 3Y with the ASX following the US registration of securities in the name of Karen Agersborg, ensuring compliance with disclosure obligations. The company emphasizes that its current practices are in line with the ASX Listing Rules, demonstrating their commitment to transparency and adherence to regulatory standards. Clinuvel, a pioneer in photomedicine, continues to develop treatments for patients with acute and life-threatening disorders, with SCENESSE® as its leading approved photoprotective drug.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.